Please login to the form below

Not currently logged in
Email:
Password:

antidepressant

This page shows the latest antidepressant news and features for those working in and with pharma, biotech and healthcare.

Janssen submits esketamine in Europe for treatment resistant depression

Janssen submits esketamine in Europe for treatment resistant depression

It has been developed for patients who have failed to respond to at least two different treatments with antidepressants in a moderate to severe depressive episode – a group which represents up ... The drug is a rapidly-acting antidepressant, and is

Latest news

  • Sage surges after depression drug gets rapid path to approval Sage surges after depression drug gets rapid path to approval

    That’s been an option for cancer drugs for a while, but this is thought to be the first time a truncated pathway has been used for an antidepressant. ... In contrast, current antidepressants can take weeks or months to start working and often come with

  • Daily Brief Daily Brief

    Two Phase III clinical studies of its esketamine nasal spray in patients with treatment-resistant depression, combined with a newly initiated oral antidepressant, produced a clinically meaningful rapid reduction of depressive

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes has been hit hard by the FDA’s rejection of antidepressant candidate ALKS 5461 - citing a lack of evidence that it was clinically effective. ... Despite the large number of approved agents, the majority of MDD patients treated with standard

  • Concordia accused of overcharging NHS for thyroid drug Concordia accused of overcharging NHS for thyroid drug

    ruling. Meanwhile, earlier in 2016 the CMA fined number of pharmaceutical companies in relation to ‘pay-for-delay’deals that affected the supply of generic paroxetine, an antidepressant developed by GlaxoSmithKline.

  • Lilly mulls divestment of its animal health operations Lilly mulls divestment of its animal health operations

    Alimta (pemetrexed) and antidepressant Cymbalta (duloxetine) resulting from generic competition.

More from news
Approximately 9 fully matching, plus 250 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Pfizer is not the only major pharma in this position; also this month GSK settled US claims of irregular marketing activities in asthma and antidepressants at a reported $105m.

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This was especially true in the “ landmark” case of Pfizer's antidepressant reboxetine, with IQWiG spending two years obtaining all the data it needed from Pfizer. “

  • Interview: Michel Goldman, Innovative Medicines Initiative Interview: Michel Goldman, Innovative Medicines Initiative

    antidepressants. "Another project, by the IMIDIA consortium on diabetes, has generated cell lines which reproduce the response of insulin-secreting cells in the pancreas, the beta cells, and these beta cell

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics